MetaCap

Vaxcyte (PCVX) vs Twist Bioscience (TWST)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Twist Bioscience (TWST) has outperformed Vaxcyte (PCVX) over the past year, gaining 261.8% versus a gain of 15.9%. Over five years, PCVX leads with a +178.9% price change compared with +8.8% for TWST. Vaxcyte is the larger company by market cap ($8.77 billion vs $7.04 billion), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PCVX+15.93%TWST+261.76%
+649%+304%-41%
Nov 21, 20251 yearNov 20, 2026
PCVX+143.90%TWST-6.60%
+436%+161%-114%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PCVX versus TWST key metrics
MetricPCVXTWST
Share price$55.39$103.32
Market cap$8.77B$7.04B
1-day change-5.09%-7.44%
YTD return+20.05%+225.73%
1-year return+15.93%+261.76%
5-year return+178.90%+8.77%
EPS (TTM)$-8.05$-2.08
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$459.43M
Revenue growth (YoY)—+22.00%
Net income (latest FY)$-766.63M$-130.20M
Gross margin—52.41%
Operating margin—-30.35%
Net margin—-28.34%
52-week high$90.75$219.71
52-week low$42.40$28.27
Distance from 52-week high-38.96%-52.97%
Analyst consensusnonebuy
Avg. price target upside+110.15%+24.68%
Average volume2.19M2.49M
Shares outstanding158.30M68.18M
Employees5071,080
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • TWST has outperformed PCVX by 245.8 percentage points over the past year.

About Vaxcyte

PCVX stock →

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 507 employees

About Twist Bioscience

TWST stock →

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; and Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, and other applications.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,080 employees

PCVX vs TWST FAQ

Which is bigger, Vaxcyte or Twist Bioscience?

Vaxcyte (PCVX) is larger, with a market capitalization of $8.77B compared with $7.04B for Twist Bioscience (TWST).

Which stock has performed better over the past year, PCVX or TWST?

TWST returned +261.76% over the past 12 months, compared with +15.93% for PCVX (price return, excluding dividends). Past performance does not predict future results.

Are Vaxcyte and Twist Bioscience in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons